Study to Evaluate the Safety and Tolerability of EP0042
Study to Evaluate the Safety and Tolerability of EP0042
Recruiting · NCT04581512 · Registry updated 2026-06-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Tolerability of EP0042 | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-22 | NCT04581512 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ellipses Pharma | 4 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Amsterdam UMC | Amsterdam | Netherlands | 1 |
| Erasmus MC | Rotterdam | Netherlands | 1 |
| Royal Perth Hospital | Perth | Australia | 43 |
| The Christie Hospital | Manchester | United Kingdom | 1 |
| The Royal Marsden | London | United Kingdom | 1 |
| University College London Hospital | London | United Kingdom | 2 |